High Prices & No Excuses : 6 Anticompetitive Games (Presentation Slides)

Brand firms have delayed generic competition even when there are no (or weak) patents. This testimony to the FTC highlights 6 such behaviors: (1) pay-for-delay settlements, (2) product hopping, (3) citizen petitions, (4) "REMS" restrictions, (5) non-REMS distribution restrictions, and (6) bundling/rebates. The testimony concludes with proposals addressing these forms of conduct

MoreLess

Year of publication:	2017
Authors:	Carrier, Michael A.
Publisher:	[2017]: [S.l.] : SSRN

freely available

Full text |

More access options

Check Google Scholar

In German libraries (KVK)

I need help

Extent:	1 Online-Ressource (10 p)
Type of publication:	Book / Working Paper
Language:	English
Notes:	In: Testimony for FTC Workshop on “Understanding Competition in Prescription Drug Markets”, 2017 Nach Informationen von SSRN wurde die ursprüngliche Fassung des Dokuments November 6, 2017 erstellt
Classification:	I18 - Government Policy; Regulation; Public Health ; K21 - Antitrust Law ; L40 - Antitrust Policy. General ; L41 - Monopolization; Horizontal Anticompetitive Practices ; L43 - Legal Monopolies and Regulation or Deregulation ; L65 - Chemicals; Rubber; Drugs; Biotechnology ; O34 - Intellectual Property Rights: National and International Issues ; O38 - Government Policy
Source:	ECONIS - Online Catalogue of the ZBW

Persistent link: https://www.econbiz.de/10012944060